Back to Search Start Over

Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy.

Authors :
LoCastro M
Sanapala C
Mendler JH
Norton S
Bernacki R
Carroll T
Klepin HD
Watson E
Liesveld J
Huselton E
O'Dwyer K
Baran A
Flannery M
Kluger B
Loh KP
Source :
Blood advances [Blood Adv] 2023 May 09; Vol. 7 (9), pp. 1871-1884.
Publication Year :
2023

Abstract

Older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) experience intense inpatient health care at the end-of-life stage. Early advance care planning may improve care at the end of life for patients with AML or MDS. The Serious Illness Care Program (SICP) is a multicomponent, communication intervention developed to improve conversations about values for patients with serious illnesses. The SICP has been shown to improve the quality and frequency of advance care planning discussions. We adapted the SICP for delivery via telehealth to older patients with AML or MDS. We conducted a single-center qualitative study of 45 participants (25 clinicians, 15 older patients with AML or MDS, and 5 caregivers). Participants, whether clinicians, patients, or caregivers, agreed that the SICP would help older patients with AML or MDS to share their personal values with their care team. Four qualitative themes emerged from our data: (1) serious illness conversations can be conducted via telehealth, (2) older patients have limited experience using technology but are willing and able to learn, (3) patients feel that serious illness conversations will help them understand their AML or MDS diagnosis and prognosis better, and (4) serious illness conversations should be common and routine, not extraordinary. The adapted SICP may provide older patients with AML or MDS an opportunity to share what matters most to them with their care team and may assist oncologists in aligning patient care with patient values. The adapted SICP is the subject of an ongoing single-arm pilot study at the Wilmot Cancer Institute (clinicaltrials.gov identifier: NCT04745676).<br /> (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Details

Language :
English
ISSN :
2473-9537
Volume :
7
Issue :
9
Database :
MEDLINE
Journal :
Blood advances
Publication Type :
Academic Journal
Accession number :
36521100
Full Text :
https://doi.org/10.1182/bloodadvances.2022008996